Haleon PLC Sponsored ADR (NYSE:HLN) Receives $12.33 Average PT from Brokerages

Key Points

• Haleon PLC has received a consensus rating of "Moderate Buy" from eleven research firms, with an average 1-year price target of $12.33.
• The company has seen significant interest from hedge funds, with firms such as Hanson & Doremus Investment Management increasing their stake by 234.1% in the second quarter.
• Shares of Haleon opened at $9.81 and have a 52-week range between $8.86 and $11.42, indicating a relatively stable performance in the market.

Haleon PLC Sponsored ADR (NYSE:HLN - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the eleven ratings firms that are covering the company, MarketBeat.com reports. Five analysts have rated the stock with a hold recommendation, four have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $12.33.

A number of analysts have recently weighed in on HLN shares. BNP Paribas upgraded shares of Haleon to a "strong-buy" rating in a report on Tuesday, May 27th. Barclays reissued an "overweight" rating on shares of Haleon in a research report on Tuesday, May 6th. Wall Street Zen downgraded shares of Haleon from a "buy" rating to a "hold" rating in a research report on Saturday, July 12th. BNP Paribas Exane raised shares of Haleon from a "neutral" rating to an "outperform" rating and set a $13.40 target price for the company in a research report on Tuesday, May 27th. Finally, Morgan Stanley raised shares of Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 target price for the company in a research report on Friday, May 9th.

Haleon Trading Up 2.5%

Shares of Haleon stock traded up $0.24 during trading on Wednesday, reaching $9.67. 16,930,452 shares of the stock were exchanged, compared to its average volume of 11,525,428. The company has a quick ratio of 0.78, a current ratio of 0.98 and a debt-to-equity ratio of 0.53. The stock's fifty day moving average is $10.37 and its 200 day moving average is $10.18. The firm has a market cap of $43.44 billion, a price-to-earnings ratio of 24.80, a price-to-earnings-growth ratio of 2.73 and a beta of 0.23. Haleon has a 1 year low of $8.86 and a 1 year high of $11.42.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of HLN. Transcend Capital Advisors LLC lifted its stake in Haleon by 52.2% in the 2nd quarter. Transcend Capital Advisors LLC now owns 23,429 shares of the company's stock worth $243,000 after purchasing an additional 8,035 shares in the last quarter. Envestnet Asset Management Inc. grew its holdings in Haleon by 6.5% during the 2nd quarter. Envestnet Asset Management Inc. now owns 7,857,196 shares of the company's stock valued at $81,479,000 after purchasing an additional 476,823 shares during the last quarter. Resonant Capital Advisors LLC grew its holdings in Haleon by 6.4% during the 2nd quarter. Resonant Capital Advisors LLC now owns 29,432 shares of the company's stock valued at $305,000 after purchasing an additional 1,761 shares during the last quarter. Bleakley Financial Group LLC bought a new position in Haleon in the 2nd quarter worth about $671,000. Finally, Pittenger & Anderson Inc. bought a new position in Haleon in the 2nd quarter worth about $36,000. Hedge funds and other institutional investors own 6.67% of the company's stock.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.